Bradmer Pharmaceuticals Inc. Report issue

For profit Phase 2 Phase 3
Founded: Ontario Canada (2005)
Status: Left NME R&D (2009)

Organization Overview

First Clinical Trial
2008
NCT00615186
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

neuradiab (2 trials)

temozolomide (temodar) (1 trial)

Drugs in Phase 2 Trials (1)

bevacizumab (avastin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Neoplasms (Phase 2)

Glioblastoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3